June 13th 2025

By Ailsa Colquhoun

Alert: Inhixa 12,000IU (120mg)/0.8mL solution for injection (PI)

Quadrant Pharmaceuticals Limited / Maxearn Limited are recalling two parallel imported batches of Inhixa 12,000IU (120mg)/0.8mL solution for injection (enoxaparin sodium).

The affected batches are:  

The Maxearn imported batches of Inhixa have incorrect strength information on  one side of the carton. The incorrect strength states “12,000 IU (20mg)/0.8 ml solution for injection” instead of the correct strength “12,000 IU (120mg)/0.8 ml solution for injection”.

The remainder of the packaging, including three other sides of the carton, the Patient Information Leaflet (PIL) and the labels on the individual pre-filled syringes all contain the correct strength details.

Only these PI batch packs are affected: packs from other sources should continue to be dispensed.

The incorrect strength is highlighted in the image of the carton below.

Healthcare professionals are asked to quarantine all stock and return it to your supplier using your supplier’s approved process.

Maxearn will arrange for customers to be contacted that have received the defective packs.

Patients who have received affected batches should be contacted and advised of the packaging error. Patients who are concerned they may have taken an incorrect dose of the medication should seek medical attention.